Sustained IL-15 release enhances CAR-T therapy in multiple myeloma via FOXO1 signaling axis activation - PubMed
5 hours ago
- #Multiple myeloma
- #IL-15 superagonist
- #CAR-T therapy
- Development of a hypoxia-responsive nanogel (BiA-N-803 NG) for controlled release of an IL-15 superagonist, dual-targeted to CD138 and TIM-3, enhances CAR-T cell therapy in multiple myeloma.
- The nanogel promotes CAR-T cell expansion, memory programming, and antitumor function, with transcriptomic profiling identifying FOXO1 signaling activation as a key mechanism.
- In vivo studies show improved CAR-T cell persistence, enhanced NK cell recruitment, reduced immunosuppressive cell infiltration, and remodeled immune microenvironment for increased therapeutic durability.